{"entity":{"id":"rock-immune","kind":"company","name":"Rock Immune","aka":["Rock Immune, Inc."],"tldr":"Rock Immune is a Denver company making immunotoxins: proteins that carry a disabled bacterial toxin straight to cancer cells. Its lead candidate, Rock425, is aimed at cutaneous T-cell lymphoma, a lymphoma of the skin.","summary":"Rock Immune, Inc. describes itself as an early-stage biopharmaceutical company developing diphtheria toxin-based recombinant immunotoxins for cancer and autoimmune disease, made in a proprietary diphtheria toxin-resistant Pichia pastoris yeast system. Its lead candidate Rock425 is a CCR4-IL2 bispecific immunotoxin for cutaneous T-cell lymphoma, which the company reports was effective in a mouse model. A 2026 National Cancer Institute STTR award funds a bivalent CD47 immunotoxin for T-cell acute lymphoblastic leukaemia.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://rockimmune.com/"},{"label":"NIH RePORTER: award 1R41CA309908-01","url":"https://reporter.nih.gov/project-details/11310680"}],"tags":[],"related":[],"cancers":["cutaneous-t-cell-lymphoma"],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":["ccr4","cd47"],"drugs":["rock425"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website and the NIH RePORTER record read on 4 November 2026. The website also mentions an earlier NCI STTR Fast Track grant of USD 2.4 million awarded in July 2021, not read on RePORTER. Founding year not stated."],"hq":"Denver, CO","country":"US","companyType":"biotech","website":"https://rockimmune.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":400000,"source":"https://reporter.nih.gov/project-details/11310680","note":"NCI STTR (R41) award 1R41CA309908-01: Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia"}]},"route":"/companies/rock-immune/","neighbours":{"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"}],"drug":[{"id":"rock425","kind":"drug","name":"Rock425","route":"/drugs/rock425/"}]}}